
Baris Turkbey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7589865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186.	5.4	24
2	Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?. Journal of Urology, 2022, 207, 95-107.	0.4	29
3	A Cascaded Deep Learning–Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. Academic Radiology, 2022, 29, 1159-1168.	2.5	21
4	Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1096-1108.	2.0	6
5	Clinical Application of Artificial Intelligence in Positron Emission Tomography: Imaging of Prostate Cancer. PET Clinics, 2022, 17, 137-143.	3.0	8
6	Deep learning-based artificial intelligence applications in prostate MRI: brief summary. British Journal of Radiology, 2022, 95, 20210563.	2.2	19
7	Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI. Abdominal Radiology, 2022, 47, 1425-1434.	2.1	18
8	Better Image Quality for Diffusion-weighted MRI of the Prostate Using Deep Learning. Radiology, 2022, , 212078.	7.3	2
9	Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI. European Radiology, 2022, 32, 2221-2223.	4.5	6
10	Development of a 3D CNN-based AI Model for Automated Segmentation of the Prostatic Urethra. Academic Radiology, 2022, 29, 1404-1412.	2.5	9
11	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. Journal of Urology, 2022, 208, 90-99.	0.4	2
12	Recent Advancements in CT and MR Imaging of Prostate Cancer. Seminars in Nuclear Medicine, 2022, 52, 365-373.	4.6	7
13	Artificial Intelligence for Automated Cancer Detection on Prostate MRI: Opportunities and Ongoing Challenges, From the <i>AJR</i> Special Series on AI Applications. American Journal of Roentgenology, 2022, 219, 188-194.	2.2	11
14	Artificial Intelligence-based Tumor Segmentation in Mouse Models of Lung Adenocarcinoma. Journal of Pathology Informatics, 2022, 13, 100007.	1.7	7
15	Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2022, , .	0.5	2
16	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology, 2022, 304, 342-350.	7.3	21
17	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. Cancers, 2022, 14, 2996.	3.7	9
18	Factors Impacting Performance and Reproducibility of PI-RADS. Canadian Association of Radiologists Journal, 2021, 72, 337-338.	2.0	8

#	Article	IF	CITATIONS
19	Quality of Prostate MRI: Is the PI-RADS Standard Sufficient?. Academic Radiology, 2021, 28, 199-207.	2.5	44
20	Quantitative Prostate <scp>MRI</scp> . Journal of Magnetic Resonance Imaging, 2021, 53, 1632-1645.	3.4	35
21	Role of multiparametric prostate MRI in the management of prostate cancer. World Journal of Urology, 2021, 39, 651-659.	2.2	24
22	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clinical Cancer Research, 2021, 27, 429-437.	7.0	22
23	Quantitative Characterization of the Prostatic Urethra Using MRI: Implications for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia. Academic Radiology, 2021, 28, 664-670.	2.5	4
24	Submucosal Enhancing Stripe: An Important Contrast-enhanced MRI Feature for Staging of Rectal Cancers. Radiology, 2021, 298, 102-103.	7.3	0
25	A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. European Radiology, 2021, 31, 4386-4389.	4.5	17
26	CT and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings. European Radiology, 2021, 31, 3165-3176.	4.5	13
27	Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. European Urology Oncology, 2021, 4, 227-234.	5.4	14
28	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. American Journal of Roentgenology, 2021, 216, 3-19.	2.2	76
29	Determination of disease severity in COVID-19 patients using deep learning in chest X-ray images. Diagnostic and Interventional Radiology, 2021, 27, 20-27.	1.5	44
30	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access, 2021, 9, 87531-87542.	4.2	12
31	Algorithms applied to spatially registered multi-parametric MRI for prostate tumor volume measurement. Quantitative Imaging in Medicine and Surgery, 2021, 11, 119-132.	2.0	8
32	Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiation Oncology, 2021, 16, 32.	2.7	11
33	PI-RADSv2.1: Current status. Turkish Journal of Urology, 2021, 47, S45-S48.	1.3	4
34	Practice Patterns and Challenges of Performing and Interpreting Prostate MRI: A Survey by the Society of Abdominal Radiology Prostate Disease–Focused Panel. American Journal of Roentgenology, 2021, 216, 952-959.	2.2	4
35	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. European Radiology, 2021, 31, 9567-9578.	4.5	34
36	Federated semi-supervised learning for COVID region segmentation in chest CT using multi-national data from China, Italy, Japan. Medical Image Analysis, 2021, 70, 101992.	11.6	140

#	Article	IF	CITATIONS
37	Can BOLD fMRI Demonstrate Early Response to Chemoembolization in HCCs?. Academic Radiology, 2021, 28 Suppl 1, S20-S21.	2.5	1
38	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology, 2021, 299, 613-623.	7.3	11
39	Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 787.e17-787.e21.	1.6	16
40	Al-Assisted CT as a Clinical and Research Tool for COVID-19. Frontiers in Artificial Intelligence, 2021, 4, 590189.	3.4	0
41	Editorial Comment: MRI for Benign Prostatic Hyperplasia—An Underutilized Imaging Opportunity. American Journal of Roentgenology, 2021, , 13.	2.2	1
42	The Importance of Quality in Prostate MRI. Seminars in Roentgenology, 2021, 56, 384-390.	0.6	6
43	Artificial Intelligence in Prostate Imaging. Advances in Clinical Radiology, 2021, 3, 15-22.	0.2	0
44	Beyond the AJR: "Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial― American Journal of Roentgenology, 2021, , 1-1.	2.2	0
45	Federated learning for predicting clinical outcomes in patients with COVID-19. Nature Medicine, 2021, 27, 1735-1743.	30.7	300
46	Correlation of prostate tumor eccentricity and Gleason scoring from prostatectomy and multi-parametric-magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2021, 11, 4235-4244.	2.0	8
47	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e1-729.e6.	1.6	6
48	The need for standardization of reporting in prostate MRI. Nature Reviews Urology, 2021, 18, 195-196.	3.8	1
49	Focal Laser Ablation for Prostate Cancer. , 2021, , 215-226.		0
50	Development and testing quantitative metrics from multi-parametric magnetic resonance imaging that predict Gleason score for prostate tumors. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	2.0	6
51	Successful SBRT for post-brachytherapy prostate recurrence and penile bulb metastasis. Advances in Radiation Oncology, 2021, , 100860.	1.2	0
52	Role of MRI in Prostate Cancer Assessment. , 2021, , 81-94.		0
53	Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. American Journal of Roentgenology, 2020, 214, 105-113.	2.2	17
54	Plâ€RADS: Past, present, and future. Journal of Magnetic Resonance Imaging, 2020, 52, 33-53.	3.4	37

#	Article	IF	CITATIONS
55	Apical periurethral transition zone lesions: MRI and histology findings. Abdominal Radiology, 2020, 45, 3258-3264.	2.1	0
56	18F-fluciclovine PET or PSMA PET for prostate cancer imaging?. Nature Reviews Urology, 2020, 17, 9-10.	3.8	3
57	Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey. Diagnostic and Interventional Radiology, 2020, 25, 421-427.	1.5	7
58	Data Augmentation and Transfer Learning to Improve Generalizability of an Automated Prostate Segmentation Model. American Journal of Roentgenology, 2020, 215, 1403-1410.	2.2	23
59	Prospective Evaluation of ¹⁸ F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. American Journal of Roentgenology, 2020, 215, 652-659.	2.2	22
60	Multicenter Multireader Evaluation of an Artificial Intelligence–Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. American Journal of Roentgenology, 2020, 215, 903-912.	2.2	29
61	PI-QUAL, a New System for Evaluating Prostate Magnetic Resonance Imaging Quality: Is Beauty in the Eye of the Beholder?. European Urology Oncology, 2020, 3, 620-621.	5.4	12
62	Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. Urology, 2020, 144, 164-170.	1.0	4
63	Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. Translational Andrology and Urology, 2020, 9, 1415-1427.	1.4	9
64	Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nature Communications, 2020, 11, 4080.	12.8	405
65	Role of mpMRI in Benign Prostatic Hyperplasia Assessment and Treatment. Current Urology Reports, 2020, 21, 55.	2.2	8
66	Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. American Journal of Roentgenology, 2020, 215, 1098-1103.	2.2	17
67	<i>RadioGraphics</i> Update: PI-RADS Version 2.1—A Pictorial Update. Radiographics, 2020, 40, E33-E37.	3.3	16
68	Improving detection of prostate cancer foci via information fusion of MRI and temporal enhanced ultrasound. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 1215-1223.	2.8	20
69	Deepâ€Learningâ€Based Artificial Intelligence for <scp>Plâ€RADS</scp> Classification to Assist Multiparametric Prostate <scp>MRI</scp> Interpretation: A Development Study. Journal of Magnetic Resonance Imaging, 2020, 52, 1499-1507.	3.4	52
70	Advances in Prostate Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 407-414.	1.1	3
71	Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. European Urology, 2020, 78, 371-378.	1.9	66
72	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. European Urology Oncology, 2020, 3, 145-167.	5.4	75

#	Article	IF	CITATIONS
73	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	27.0	515
74	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of ¹⁸ F-DCFPyL PET/CT with Comparison to Multiparametric MRI. Radiology, 2020, 296, 564-572.	7.3	24
75	A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications, 2020, 11, 837.	12.8	28
76	Positron emission tomography (PET) radiotracers for prostate cancer imaging. Abdominal Radiology, 2020, 45, 2165-2175.	2.1	18
77	Can fast bi-parametric MRI help prostate cancer detection in biopsy naive men?. Chinese Clinical Oncology, 2020, 9, 40-40.	1.2	1
78	What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. American Journal of Roentgenology, 2020, 214, 1211-1219.	2.2	4
79	Impact of bowel preparation with Fleet's™ enema on prostate MRI quality. Abdominal Radiology, 2020, 45, 4252-4259.	2.1	26
80	Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer. Expert Review of Medical Devices, 2020, 17, 435-442.	2.8	9
81	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	7.3	207
82	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. Journal of Urology, 2020, 203, 706-712.	0.4	152
83	Rapid perceptual processing in two- and three-dimensional prostate images. Journal of Medical Imaging, 2020, 7, 1.	1.5	7
84	Tracked Foley catheter for motion compensation during fusion image-guided prostate procedures: a phantom study. European Radiology Experimental, 2020, 4, 24.	3.4	0
85	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients Journal of Clinical Oncology, 2020, 38, e17567-e17567.	1.6	1
86	Molecular Imaging of Prostate Cancer. , 2020, , 171-190.		0
87	PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. Journal of Urology, 2020, 204, 1229-1235.	0.4	5
88	Local staging of prostate cancer with imaging: can hybrid imaging be the solution?. Translational Andrology and Urology, 2020, 9, 834-836.	1.4	0
89	Radiomics and radiogenomics of prostate cancer. Abdominal Radiology, 2019, 44, 2021-2029.	2.1	43
90	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	1.9	200

#	Article	IF	CITATIONS
91	Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?. World Journal of Urology, 2019, 37, 235-241.	2.2	31
92	Detecting Prostate Cancer with Deep Learning for MRI: A Small Step Forward. Radiology, 2019, 293, 618-619.	7.3	24
93	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology, 2019, 290, 709-719.	7.3	140
94	Prostate Magnetic Resonance Imaging: Lesion Detection and Local Staging. Annual Review of Medicine, 2019, 70, 451-459.	12.2	3
95	Reply to Byung Kwan Park's Letter to the Editor re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:329–40. European Urology, 2019, 76, e79.	1.9	0
96	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	7.3	162
97	Artificial intelligence at the intersection of pathology and radiology in prostate cancer. Diagnostic and Interventional Radiology, 2019, 25, 183-188.	1.5	62
98	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351.	1.9	1,270
99	Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?. American Journal of Roentgenology, 2019, 212, 1244-1252.	2.2	7
100	Novel Imaging in Detection of Metastatic Prostate Cancer. Current Oncology Reports, 2019, 21, 31.	4.0	13
101	Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. American Journal of Roentgenology, 2019, 212, 1197-1205.	2.2	75
102	Intra―and interreader reproducibility of Plâ€RADSv2: A multireader study. Journal of Magnetic Resonance Imaging, 2019, 49, 1694-1703.	3.4	102
103	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). Academic Radiology, 2019, 26, 5-14.	2.5	12
104	Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. Journal of Urology, 2019, 201, 84-90.	0.4	24
105	When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer. Journal of Urology, 2019, 201, 943-949.	0.4	5
106	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. Turkish Journal of Urology, 2019, 45, 357-365.	1.3	18
107	Diffusion-Weighted Imaging in Magnetic Resonance Imaging of theÂProstate. , 2018, , 167-178.		0
108	A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology, 2018, 4, 678.	7.1	141

#	Article	IF	CITATIONS
109	Prospective comparison of Plâ€RADS version 2 and qualitative inâ€house categorization system in detection of prostate cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1326-1335.	3.4	18
110	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. European Radiology, 2018, 28, 4407-4417.	4.5	68
111	Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology—Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?. Journal of Urology, 2018, 199, 976-982.	0.4	89
112	Pilot study for supervised target detection applied to spatially registered multiparametric MRI in order to non-invasively score prostate cancer. Computers in Biology and Medicine, 2018, 94, 65-73.	7.0	12
113	All over the map: An interobserver agreement study of tumor location based on the Plâ€RADSv2 sector map. Journal of Magnetic Resonance Imaging, 2018, 48, 482-490.	3.4	31
114	Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Radiologic Clinics of North America, 2018, 56, 263-275.	1.8	45
115	Future Perspectives and Challenges of Prostate MR Imaging. Radiologic Clinics of North America, 2018, 56, 327-337.	1.8	11
116	A Prospective Comparison of ¹⁸ F-Sodium Fluoride PET/CT and PSMA-Targeted ¹⁸ F-DCFBC PET/CT in Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1665-1671.	5.0	40
117	The Problems with the Kappa Statistic as a Metric of Interobserver Agreement on Lesion Detection Using a Third-reader Approach When Locations Are Not Prespecified. Academic Radiology, 2018, 25, 1325-1332.	2.5	9
118	Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging. Urology, 2018, 116, 3-12.	1.0	21
119	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology, 2018, 286, 186-195.	7.3	188
120	Using Imaging to Predict Treatment Response in Genitourinary Malignancies. European Urology Focus, 2018, 4, 804-817.	3.1	3
121	Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 4-11.	6.4	57
122	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. International Urology and Nephrology, 2018, 50, 7-12.	1.4	19
123	Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer. Translational Andrology and Urology, 2018, 7, S453-S461.	1.4	20
124	Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. Translational Andrology and Urology, 2018, 7, 831-843.	1.4	35
125	PI-RADS v2: Current standing and future outlook. Turkish Journal of Urology, 2018, 44, 189-194.	1.3	13
126	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	2.5	16

#	Article	IF	CITATIONS
127	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagnostic and Interventional Radiology, 2018, 24, 46-53.	1.5	21
128	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. Radiology, 2018, 288, 485-491.	7.3	53
129	Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 341.e1-341.e7.	1.6	23
130	Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15Âmm the best threshold?. Abdominal Radiology, 2018, 43, 3436-3444.	2.1	13
131	Prostate MR Imaging for Posttreatment Evaluation and Recurrence. Urologic Clinics of North America, 2018, 45, 467-479.	1.8	24
132	Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems. American Journal of Roentgenology, 2018, 211, W33-W41.	2.2	26
133	Deep dense multi-path neural network for prostate segmentation in magnetic resonance imaging. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 1687-1696.	2.8	47
134	Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. Journal of Urology, 2018, 200, 1041-1047.	0.4	66
135	Prostate cancer detection from multi-institution multiparametric MRIs using deep convolutional neural networks. Journal of Medical Imaging, 2018, 5, 1.	1.5	37
136	Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. Oncotarget, 2018, 9, 33804-33817.	1.8	65
137	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655.	1.9	190
138	Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer. JAMA Oncology, 2017, 3, 1415.	7.1	42
139	PI-RADSv2: How we do it. Journal of Magnetic Resonance Imaging, 2017, 46, 11-23.	3.4	13
140	Role of Magnetic Resonance Imaging in Prostate Cancer Assessment. Current Clinical Urology, 2017, , 161-176.	0.0	0
141	Detection of prostate cancer in multiparametric MRI using random forest with instance weighting. Journal of Medical Imaging, 2017, 4, 024506.	1.5	33
142	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 473-491.	1.6	44
143	Prospective Evaluation of PI-RADSâ,,¢ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology, 2017, 198, 583-590.	0.4	127
144	The Current State of MR Imaging–targeted Biopsy Techniques for Detection of Prostate Cancer. Radiology, 2017, 285, 343-356.	7.3	88

#	Article	IF	CITATIONS
145	Current Role of Magnetic Resonance Imaging in Prostate Cancer. Current Radiology Reports, 2017, 5, 1.	1.4	1
146	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology, 2017, 285, 859-869.	7.3	126
147	18F-DCFBC Prostate-Specific Membrane Antigen–Targeted PET/CT Imaging in Localized Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, 735-740.	1.3	23
148	Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges. Radiology, 2017, 285, 728-743.	7.3	38
149	Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. Journal of Urology, 2017, 197, 327-334.	0.4	84
150	Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 30.e1-30.e8.	1.6	42
151	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 640-646.	0.4	90
152	Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. Journal of Magnetic Resonance Imaging, 2017, 45, 579-585.	3.4	170
153	Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. Journal of Magnetic Resonance Imaging, 2017, 45, 125-131.	3.4	38
154	Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 610-616.	3.4	23
155	Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?. Urology, 2017, 105, 113-117.	1.0	12
156	Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. Translational Andrology and Urology, 2017, 6, 413-423.	1.4	34
157	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. Radiology, 2017, 285, 147-156.	7.3	33
158	Quantitative Image Quality Comparison of Reduced- and Standard-Dose Dual-Energy Multiphase Chest, Abdomen, and Pelvis CT. Tomography, 2017, 3, 114-122.	1.8	10
159	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	3.8	26
160	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	3.8	16
161	Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Quantitative Multiparametric Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2016, 40, 218-224.	0.9	12
162	Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification. International Urology and Nephrology, 2016, 48, 1445-1452.	1.4	9

#	Article	IF	CITATIONS
163	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.7	6
164	A urologist's perspective on prostate cancer imaging: past, present, and future. Abdominal Radiology, 2016, 41, 805-816.	2.1	25
165	The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 254.e15-254.e21.	1.6	25
166	Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 2016, 280, 793-804.	7.3	398
167	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Journal of the National Cancer Institute, 2016, 108, djw039.	6.3	68
168	Engaging and educating patients in prostate imaging via social media. Abdominal Radiology, 2016, 41, 798-798.	2.1	8
169	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.4	116
170	PSMA PET and Radionuclide Therapy in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 522-535.	4.6	82
171	Does Abstinence From Ejaculation Before Prostate MRI Improve Evaluation of the Seminal Vesicles?. American Journal of Roentgenology, 2016, 207, 1205-1209.	2.2	28
172	Evaluation of Prostate Cancer with PET/MRI. Journal of Nuclear Medicine, 2016, 57, 111S-116S.	5.0	29
173	Reply to "Standardizing Biparametric MRI to Simplify and Improve Prostate Imaging Reporting and Data System, Version 2, in Prostate Cancer Management― American Journal of Roentgenology, 2016, 207, W76-W76.	2.2	2
174	Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. Ca-A Cancer Journal for Clinicians, 2016, 66, 326-336.	329.8	128
175	Birth of a standard: MET-RADS-P for metastatic prostate cancer. Nature Reviews Urology, 2016, 13, 568-570.	3.8	4
176	Incorporating imaging into personalized medicine for the detection of prostate cancer. Pharmacological Research, 2016, 114, 163-165.	7.1	1
177	Advancement of MR and PET/MR in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 536-543.	4.6	21
178	Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. Topics in Magnetic Resonance Imaging, 2016, 25, 139-147.	1.2	44
179	Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. Acta Radiologica, 2016, 57, 1396-1401.	1.1	8
180	Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling. Journal of Urology, 2016, 196, 62-67.	0.4	20

#	Article	IF	CITATIONS
181	Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort. Journal of Urology, 2016, 195, 1737-1743.	0.4	18
182	Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. American Journal of Roentgenology, 2016, 206, 1179-1183.	2.2	92
183	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118.	2.1	35
184	DCE MRI of prostate cancer. Abdominal Radiology, 2016, 41, 844-853.	2.1	56
185	Evaluating the Role of mpMRI in Prostate Cancer Assessment. Expert Review of Medical Devices, 2016, 13, 129-141.	2.8	13
186	Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. Urology, 2016, 88, 125-134.	1.0	81
187	Imaging in Localized Prostate Cancer. , 2016, , 91-99.		0
188	Imaging of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 147-155.	1.6	41
189	Comparison of magnetic resonance imaging and ultrasound (<scp>MRlâ€US</scp>) fusionâ€guided prostate biopsies obtained from axial and sagittal approaches. BJU International, 2015, 115, 772-779.	2.5	45
190	A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis. Case Reports in Urology, 2015, 2015, 1-3.	0.3	7
191	PIRADS 2.0: what is new?. Diagnostic and Interventional Radiology, 2015, 21, 382-384.	1.5	38
192	The Role of MRI in Active Surveillance for Prostate Cancer. Current Urology Reports, 2015, 16, 42.	2.2	43
193	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. Abdominal Imaging, 2015, 40, 2557-2565.	2.0	34
194	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. Journal of Urology, 2015, 193, 1943-1949.	0.4	60
195	The Role of Image Guided Biopsy Targeting in Patients with Atypical Small Acinar Proliferation. Journal of Urology, 2015, 193, 473-478.	0.4	30
196	Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer. Abdominal Imaging, 2015, 40, 578-586.	2.0	58
197	Recent advances in image-guided targeted prostate biopsy. Abdominal Imaging, 2015, 40, 1788-1799.	2.0	48
198	Interactive Feature Space Explorer© for multi-modal magnetic resonance imaging. Magnetic Resonance Imaging, 2015, 33, 804-815.	1.8	2

#	Article	IF	CITATIONS
199	A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer. American Journal of Roentgenology, 2015, 205, 64-69.	2.2	57
200	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 2015, 277, 741-750.	7.3	296
201	Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	7.4	1,267
202	Automated prostate cancer detection using <i>T</i> 2â€weighted and highâ€ <i>b</i> â€value diffusionâ€weighted magnetic resonance imaging. Medical Physics, 2015, 42, 2368-2378.	3.0	81
203	Lymph Node Staging in Prostate Cancer. Current Urology Reports, 2015, 16, 30.	2.2	45
204	Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. Radiology, 2015, 276, 479-489.	7.3	53
205	Magnetic Resonance Sentinel Lymph Node Imaging of the Prostate with Gadofosveset Trisodium–Albumin. Academic Radiology, 2015, 22, 646-652.	2.5	17
206	Prostate Cancer: Top Places Where Tumors Hide on Multiparametric MRI. American Journal of Roentgenology, 2015, 204, W449-W456.	2.2	37
207	The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. Journal of Urology, 2015, 194, 105-111.	0.4	56
208	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e1-202.e7.	1.6	133
209	Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?. Abdominal Imaging, 2015, 40, 3222-3229.	2.0	22
210	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion–assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e1-425.e6.	1.6	32
211	In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12 ore biopsy still necessary in addition to a targeted biopsy?. BJU International, 2015, 115, 562-570.	2.5	125
212	Diagnostic value of biparametric magnetic resonance imaging (<scp>MRI</scp>) as an adjunct to prostateâ€specific antigen (<scp>PSA</scp>)â€based detection of prostate cancer in men without prior biopsies. BJU International, 2015, 115, 381-388.	2.5	128
213	Multiparametric MRI in Prostate Cancer. BioMed Research International, 2014, 2014, 1-3.	1.9	8
214	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) and subsequent <scp>MRI</scp> /ultrasonography fusionâ€guided biopsy increase the detection of anteriorly located prostate cancers. BJU International, 2014, 114, E43-E49.	2.5	103
215	A decade in image-guided prostate biopsy. Nature Reviews Urology, 2014, 11, 611-612.	3.8	7
216	Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research. BioMed Research International, 2014, 2014, 1-11.	1.9	90

#	Article	IF	CITATIONS
217	Localized Prostate Cancer Detection with ¹⁸ F FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis. Radiology, 2014, 270, 849-856.	7.3	141
218	MR lymphangiography with intradermal gadofosveset and human serum albumin in mice and primates. Journal of Magnetic Resonance Imaging, 2014, 40, 691-697.	3.4	9
219	Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia. Diagnostic and Interventional Radiology, 2014, 20, 229-233.	1.5	41
220	Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urology Practice, 2014, 1, 13-21.	0.5	7
221	Magnetic Resonance Lymphography of the Thoracic Duct after Interstitial Injection of Gadofosveset Trisodium: A Pilot Dosing Study in a Porcine Model. Lymphatic Research and Biology, 2014, 12, 32-36.	1.1	13
222	Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole-mount histopathology. Journal of Magnetic Resonance Imaging, 2014, 39, 1443-1448.	3.4	138
223	Role of Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer. Current Urology Reports, 2014, 15, 387.	2.2	13
224	Current status of magnetic resonance imaging (<scp>MRI</scp>) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU International, 2014, 114, 641-652.	2.5	111
225	Multiparametric Magnetic Resonance Imaging and Image-Guided Biopsy to Detect Seminal Vesicle Invasion by Prostate Cancer. Journal of Endourology, 2014, 28, 1283-1289.	2.1	45
226	Identification of Threshold Prostate Specific Antigen Levels to Optimize the Detection of Clinically Significant Prostate Cancer by Magnetic Resonance Imaging/Ultrasound Fusion Guided Biopsy. Journal of Urology, 2014, 192, 1642-1649.	0.4	55
227	Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy. Journal of Urology, 2014, 191, 1749-1754.	0.4	167
228	Prostate Biopsy for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2014, 25, 675-684.	0.5	15
229	Multiparametric MRI in prostate cancer management. Nature Reviews Clinical Oncology, 2014, 11, 346-353.	27.6	127
230	Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagnostic and Interventional Radiology, 2014, 20, 293-298.	1.5	60
231	Image-guided focal therapy for prostate cancer. Diagnostic and Interventional Radiology, 2014, 20, 492-497.	1.5	20
232	Intravoxel incoherent motion MR imaging for prostate cancer: An evaluation of perfusion fraction and diffusion coefficient derived from different <i>b</i> â€value combinations. Magnetic Resonance in Medicine, 2013, 69, 553-562.	3.0	169
233	Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer. Journal of Urology, 2013, 190, 1721-1727.	0.4	171
234	Functional and molecular imaging of localized and recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 48-59.	6.4	26

#	Article	IF	CITATIONS
235	Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology, 2013, 64, 713-719.	1.9	436
236	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. European Urology, 2013, 64, 544-552.	1.9	383
237	Can Magnetic Resonance-Ultrasound Fusion Biopsy Improve Cancer Detection in Enlarged Prostates?. Journal of Urology, 2013, 190, 2020-2025.	0.4	73
238	Fully Automated Prostate Segmentation on MRI: Comparison With Manual Segmentation Methods and Specimen Volumes. American Journal of Roentgenology, 2013, 201, W720-W729.	2.2	52
239	Prostate Cancer: Can Multiparametric MR Imaging Help Identify Patients Who Are Candidates for Active Surveillance?. Radiology, 2013, 268, 144-152.	7.3	201
240	Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer, 2013, 119, 3359-3366.	4.1	205
241	Magnetic resonance imaging (<scp>MRI</scp>)â€guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised <scp>MRI</scp> â€based moulds. BJU International, 2013, 112, 508-516.	2.5	31
242	MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes. Canadian Journal of Urology, 2013, 20, 7002-7.	0.0	5
243	11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation. Journal of Nuclear Medicine, 2012, 53, 538-545.	5.0	119
244	Active surveillance for prostate cancer. Current Opinion in Oncology, 2012, 24, 243-250.	2.4	41
245	Multiparametric MRI and prostate cancer diagnosis and risk stratification. Current Opinion in Urology, 2012, 22, 310-315.	1.8	105
246	The Kinetics and Reproducibility of ¹⁸ F-Sodium Fluoride for Oncology Using Current PET Camera Technology. Journal of Nuclear Medicine, 2012, 53, 1175-1184.	5.0	71
247	Ageâ€related changes in prostate zonal volumes as measured by highâ€resolution magnetic resonance imaging (MRI): a crossâ€sectional study in over 500 patients. BJU International, 2012, 110, 1642-1647.	2.5	45
248	Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management. American Journal of Roentgenology, 2012, 198, 1277-1288.	2.2	248
249	Use of Patient-specific MRI-based Prostate Mold for Validation of Multiparametric MRI in Localization of Prostate Cancer. Urology, 2012, 79, 233-239.	1.0	61
250	Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU International, 2012, 110, E694-700.	2.5	52
251	Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of highâ€risk prostate cancer. BJU International, 2012, 110, E783-8.	2.5	91
252	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.4	188

#	Article	IF	CITATIONS
253	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157.	0.4	227
254	D'Amico Risk Stratification Correlates With Degree of Suspicion of Prostate Cancer on Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2011, 185, 815-820.	0.4	113
255	Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2011, 186, 1281-1285.	0.4	408
256	Multiparametric 3T Prostate Magnetic Resonance Imaging to Detect Cancer: Histopathological Correlation Using Prostatectomy Specimens Processed in Customized Magnetic Resonance Imaging Based Molds. Journal of Urology, 2011, 186, 1818-1824.	0.4	440
257	Documenting the location of prostate biopsies with image fusion. BJU International, 2011, 107, 53-57.	2.5	55
258	Accelerated <i>T</i> ₂ mapping for characterization of prostate cancer. Magnetic Resonance in Medicine, 2011, 65, 1400-1406.	3.0	62
259	ls Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?. Radiology, 2011, 258, 488-495.	7.3	372
260	Magnetic resonance imaging of localized prostate cancer: coming of age in the psa era. Diagnostic and Interventional Radiology, 2011, 18, 34-45.	1.5	26
261	Imaging Prostate Cancer: An Update on Positron Emission Tomography and Magnetic Resonance Imaging. Current Urology Reports, 2010, 11, 180-190.	2.2	44
262	Discrete Deformable Model Guided by Partial Active Shape Model for TRUS Image Segmentation. IEEE Transactions on Biomedical Engineering, 2010, 57, 1158-1166.	4.2	100
263	Prostate Cancer: Value of Multiparametric MR Imaging at 3 T for Detection—Histopathologifc Correlation. Radiology, 2010, 255, 89-99.	7.3	441
264	Prostate MRI and 3D MR Spectroscopy: How We Do It. American Journal of Roentgenology, 2010, 194, 1414-1426.	2.2	80
265	A method for correlating <i>in vivo</i> prostate magnetic resonance imaging and histopathology using individualized magnetic resonance -based molds. Review of Scientific Instruments, 2009, 80, 104301.	1.3	102
266	Imaging Localized Prostate Cancer: Current Approaches and New Developments. American Journal of Roentgenology, 2009, 192, 1471-1480.	2.2	181
267	Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Computer Aided Surgery, 2008, 13, 255-264.	1.8	272